LATEST NEWS
New Publication - SG2274 Gene-Targeting AgentFri 4th Jul 08
Latest publication: Kotecha M. et al. (2008). Inhibition of DNA binding of the NF-Y transcriptio
LATEST PRESS RELEASE
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000Thu 8th Oct 09
London, United Kingdom, 08 October, 2009 - Spirogen Limited (Spirogen), the UK-based developer of DN
SECURE AREA
A clinical stage Biotechnology company creating potent small molecules based on novel mechanisms and chemistry to target important cancers.
The company has significant experience utilizing cutting edge technologies to make effective DNA sequence targeted agents.